drugset / Trial / NCT05193916
A Phase II Clinical Trial of Chiglitazar for NASH
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is to evaluate the efficacy and safety of chiglitazar monotherapy in patients with non-clcoholic steatohepatitis (NASH).
Timeline
- Start
- 2022-03-21
- Primary completion
- 2024-01-02
- Completion
- 2024-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chiglitazar | Unknown | 48 mg | Oral |
| Subject | Chiglitazar | Unknown | 64 mg | Oral |